12.01.2012 20:35 Uhr, Quelle: Wallstreet online

Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease

SAN DIEGO, January 12, 2012 /PRNewswire/ Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues …

Weiterlesen bei Wallstreet online